SLC5A2 and liver cancer: Studies have showed that SGLT2 is expressed in liver cancer cells, and canagliflozin can inhibit the proliferation of liver cancer cells by blocking glucose uptake [31,32], while another study has reported that canagliflozin can inhibit the proliferation of liver cancer cells independently of SGLT2 inhibition, possibly by blocking the glucose influx-induced β-catenin signaling pathway [33].